Kornimate/medical-research-clean huggingface dataset:
intraoperative tumor margin identification with icg dye imaging

Conditions: Benign Neoplasm; Malignant Neoplasm

Summary: in this research study we want to learn more about the use of indocyanine green (icg) during bone or soft tissue mass resections. indocyanine green (icg) is a type of dye that is used in medical diagnostics. we want to determine if icg-guided tumor resection is more effective in obtaining negative margins. lastly, we want to assess traditional oncologic outcomes of local recurrence, time to metastatic disease, and overall and disease specific survival.

if you are present for a preoperative clinic visit the day before your surgery, icg may be administered via injection. otherwise, icg will be administered in the preoperative unit via iv injection at the time of presentation approximately 4 hours before your surgery. you will be monitored during and after icg dosing. during surgery icg fluorescence using a near-infrared imager will be performed at the time of and immediately following primary tumor resection. the imager will evaluate the primary tumor to ensure appropriate tumor fluorescence. once the primary resection is complete and the surgeon believes that he/she has achieved negative or planned positive margins, fluorescence measurements of the tumor bed will be performed. if areas of positive signal remain, these areas will be resected if possible and sent to pathology for histologic evaluation. it will be recorded if the surgeon perceived negative margins but the device detected positive margins. tumor specimens and residual fluorescence positive samples will be evaluated using fresh frozen and permanent histology. permanent samples will be evaluated for tumor and local fluorescence using confocal microscopy with an icg cube. positive fluorescence signal and its correspondence with neoplasm will be noted, a will tumor that does not fluoresce. tissue being removed is 1-2 mm from non-structurally important tissue that either has or does not have signal positivity for additional pathologic assessment. it should have no impact on patient outcome, does not represent intervention on sensitive areas (such as neurovascular structures), and can further be used as potential margin around the tumor.

Eligibility criteria:
inclusion criteria: * all patients 18 years of age or older who present to massachusetts general hospital department of orthopaedic surgery with a benign or malignant bone or soft tissue mass that is consented for surgery during the study period. exclusion criteria: * pregnant or nursing patients * patients with previously known anaphylaxis to iv contrast or iodine (other allergies may be considered on a case-by-case basis) * patients in renal failure who are not cleared for icg administration by their primary physician or oncologist
adherence of hispanic / latina breast cancer - patients to adjuvant aromatase inhibitors

Conditions: Breast Cancer

Summary: this is an observational trial designed to assess prospectively the adherence rate to ais among women with invasive breast cancer (stages i-iii) currently receiving ai adjuvant therapy after standard local and systemic therapy. we will study adherence by administrating the 8-item morisky medication adherence scale (mmas - 8).

* women with breast cancer seen at the texas tech physicians breast care center will be recruited during their routine follow-up visit with their medical oncologist. * post - menopausal women with histologically confirmed hormonal positive (er and/or pr) invasive breast cancer stages i - iii with no evidence of metastatic disease (m0). * patients must be on one of ai (steroidal or non-steroidal). * patient must have completed local treatment (surgery /radiation) and recovered from all side effects of chemotherapy and surgery. * patient must be able to complete a demographic and the mmas - 8 questionnaires in english or spanish.

Eligibility criteria:
inclusion criteria: * post - menopausal women with histologically confirmed hormonal positive (er and/or pr) invasive breast cancer stages i - iii with no evidence of metastatic disease (m0). * patient must have completed local treatment (surgery /radiation) and recovered from all side effects of chemotherapy and surgery. * patient must be on one of ai (steroidal or non-steroidal). * patient must be able to complete a demographic and the mmas - 8 questionnaires in english or spanish exclusion criteria: * \< 18 years old
a study of ery974 in patient with advanced solid tumors

Conditions: Solid Tumors

Summary: this is the open label, multicenter phase 1 study which consists of a dose escalation to determine the maximum tolerated dose (mtd) and cohort expansion to obtain a preliminary evaluation of anti-tumor activity. ery974 is intravenously injected to patients with glypican 3 positive advanced solid tumors until unacceptable toxicity or disease progression.


Eligibility criteria:
inclusion criteria: * male or female patient with glypican 3 positive advanced solid tumor not amenable to standard therapy or for which standard therapy is not available or not indicated * measurable tumor * eastern cooperative oncology group (ecog) performance status 0 to 1 * adequate bone marrow, liver, and renal function * adequate coagulation status exclusion criteria: * patients with more than a single brain metastasis ( \>1 cm) * patients with acute or chronic infection * major surgery within 28 days * pregnant or lactating women * patients with interstitial pneumonitis * patients require regular ascites/pleural effusion drainage
a clinical study of ifinatamab deruxtecan (i-dxd) in people with metastatic prostate cancer (mk-2400-001)

Conditions: Prostate Cancer; Prostatic Neoplasms

Summary: researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mcrpc). researchers have designed a study medicine called ifinatamab deruxtecan (also called i-dxd or mk-2400) to treat mcrpc. the goal of this study is to learn if people who receive i-dxd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy,


Eligibility criteria:
inclusion criteria: the main inclusion criteria include but are not limited to the following: * has diagnosis of metastatic castration-resistant prostate cancer (mcrpc) * has prostate cancer progression while on androgen deprivation therapy (adt) (or post bilateral orchiectomy) within 6 months prior to entering the study * has received prior treatment with 1 or 2 androgen receptor pathway inhibitor (arpi) and progressed during or after at least 8 weeks of treatment exclusion criteria: the main exclusion criteria include but are not limited to the following: * history of (non-infectious) interstitial lung disease (ild)/pneumonitis that required steroids * has uncontrolled or significant cardiovascular disease * has received prior treatment with a taxane-based chemotherapy agent for mcrpc
interchangeability of right ventricle longitudinal shortening in echocardiography

Conditions: Right Ventricle; Speckle Tracking; Strains; Cardiac Surgery

Summary: rv longitudinal shortening fraction (rv-slf) is based on the analysis of the tricuspid annulus displacement (tad) and can be performed in transthoracic (tte) or transoesophageal echocardiography (tee). having an 2d-ste interchangeable parameter would allow accurate measurement of rv systolic function before, during and after cardiac surgery. however, to date, there are no data on the interchangeability of rv-lsf measurements performed in tte and tee. the aim of the study is to evaluate the interchangeability of tte and tee measurements of rv-lsf during cardiopulmonary bypass surgery.


Eligibility criteria:
inclusion criteria: * adult patient (\>18 years) * patient hospitalized at the amiens university hospital for scheduled cardiac surgery under cardiopulmonary bypass. * information of the patient and collection of his non-opposition exclusion criteria: * patient with a contraindication to the realization of tee (gastric or mediastinal pathology) * patient with poor echogenicity on tee not allowing evaluation of 2d-ste parameters of the right ventricle * patient with a rapid supraventricular rhythm disorder (hr \> 100) at the time of tte and/or tee.

Keywords: right ventricle speckle tracking strains cardiac surgery
robot-aided neurorehabilitation of the upper extremities

Conditions: Robot-aided Arm Therapy, Brain Injury, Motor Relearning Programme, Activities of Daily Living

Summary: task-oriented repetitive movement can improve movement performance in patients with neurological or orthopedic lesions. the application of robotics can serve to assist, enhance, evaluate, and document neurological and orthopedic rehabilitation of movements. arm therapy is used in neurological rehabilitation for patients with paralyzed upper extremities due to lesions of the central or peripheral nervous system, e.g. after stroke or spinal cord injury. the goal of the therapy is to recover motor function, improve movement coordination, learn new motion strategies ("trick movements"), and/or prevent secondary complications such as muscle atrophy, osteoporosis, and spasticity.


Eligibility criteria:
inclusion criteria: patients with neurological disability of the upper limb with qualification for arm training, e.g. after stroke and spinal cord injury exclusion criteria: * limitations of the join mobility * osteoporosis * cardiovascular disease * injury of the upper limb * decubitus * psychic diseases (like schizophrenia, dementia, depression) * body weight \> 120kg * pacemaker.
serum markers in preeclamptic women

Conditions: Preeclampsia

Summary: could possible markers in serum obtained in the first trimester predict the human-pregnancy specific disorder pre-eclampsia?


Eligibility criteria:
inclusion criteria: * previous healthy exclusion criteria: * previous inflammatory diseases

Keywords: preeclampsia serological bio-bank adiponectin supar
effects of breathing exercises combined with endurance and strength training in patients with cystic fibrosis.

Conditions: Cystic Fibrosis Patients

Summary: cystic fibrosis (cf) is a multi-system inherited disease. it's a common autosomal recessive illness. it mostly affects the lungs, liver, and pancreatic exocrine glands, as well as the intestines. the production of viscous mucus and an environment prone to chronic airway blockage. this allows harmful microorganisms to infect the lungs. the role of exercise as a prognostic indicator or therapeutic aid is important in cf research around the world. the objective of this study is to find out the effects of breathing exercises combined with endurance and strength training on dyspnea and quality of life of patients with cystic fibrosis. it will be quasi experimental study. treatment will be given to all participants 3 sessions in a week for 4 weeks. pre and post treat-meant evaluation will be checked by cfq-r+14. all patients will be treated with exercise program of active cycle breathing techniques(acbt), pursed lip breathing, endurance exercise 20 to 30 min ( walking, cycling) and strength training with thera-bands (bilateral arm raising, bilateral knee extension). exercise capacity will be measured with 6mwt. dyspnea and fatigue will be measured with borg scale.


Eligibility criteria:
inclusion criteria: * age 14-50 years * male and female both will be included * clinically stable * shortness of breath on effort exclusion criteria: * smoking history \>10 years * clinical diagnosis of asthma * physical and psychological disability preventing participation * medical condition which could place individuals at risk during exercise training

Keywords: cystic fibrosis active cycle breathing technique 6 minute walk test borg scale quality of life
high-resolution mri of atrial fibrillation patients prior to focal impulse and rotor modulation (firm) ablation

Conditions: Atrial Fibrillation

Summary: patients undergoing firm guided ablation of atrial fibrillation will undergo high resolution mri imaging to determine correlation of underlying anatomic fibrotic regions with firm targeted sites for ablation.

the project will be a prospective trial involving patients consented for a clinically indicated atrial fibrillation (af) ablation using firm mapping. the purpose of the study is to collect additional information before, during, and after the ablation procedure. all patients will undergo a contrast-enhance mri scanning with gadolinium-based contrast agent prior to the procedure as it provides a 3-dimensional image of both the left atria and right atria. the primary endpoint of this study will be the presence or absence of a correlation between micro-anatomic fibrotic tracks, determined by a combination of atrial wall thickness, and local scar and fibrosis, and sites of firm map indicated rotor activity. medical information will also be collected after the patients 2nd, 3rd and 6 month standard of care doctor visits. there are no additional risks associated with this protocol over and above that of the standard risk of atrial fibrillation ablation with firm, and those associated with the standard risk of magnetic resonance imaging with gadolinium contrast agent, but there is a small risk of the loss of confidentiality when participating in an observational study. the potential benefits includes the possibility of greater understanding of the patient's specific disease state.

Eligibility criteria:
inclusion criteria: 1. patients with symptomatic paroxysmal or persistent atrial fibrillation undergoing clinically-indicated ablation procedure employing firm mapping with pre-operative mri. 2. subjects must be at least 18 years of age. exclusion criteria: 1. laa thrombus present on pre-procedure tee 2. unable to undergo mri imaging 3. unable to receive gadolinium contrast.

Keywords: ablation atrial fibrillation firm
intraprostatic maximal simultaneous boost

Conditions: Prostate Cancer

Summary: this trial uses a type of radiotherapy called intensity modulated radiotherapy (imrt), which is able to deliver the radiation to the prostate while delivering less dose to the surrounding normal organs compared with standard 3d conformal radiotherapy presently used at the bcca. this trial will use rapidarc imrt, which is a new way of delivering imrt, where the radiation dose is delivered in a single rotation of the radiotherapy machine around the patient. this new method of delivering imrt has been shown to be at least as good as conventional imrt at delivering the dose, and takes less time to do so. the aim of this study is to deliver a higher radiation dose to the prostate gland than the standard treatment while not increasing dose to the normal organs. in this way, it is hoped that the likelihood of the cancer coming back will be reduced without causing an increase in side-effects.


Eligibility criteria:
inclusion criteria: 1. patients must have histologically proven adenocarcinoma of the prostate. 2. registration must occur within 26 weeks of biopsy. 3. history and physical examination (including digital rectal examination (dre)) within 8 weeks prior to registration. 4. patients must have intermediate risk prostate cancer, as defined by: * psa ≤ 20 ng/ml, * gleason ≤ 7, * stage ≤ t2c, and * do not meet criteria for low-risk prostate cancer (low-risk = all of: psa ≤ 10 + gleason ≤ 6 + stage ≤ t2b) 5. patients must have the following blood tests within two weeks of registration: * prostate specific antigen (psa), testosterone (ttt), complete blood count (cbc), electrolytes, creatinine. * patients with values for one or more of these tests (not including psa) that fall outside the normal range will need to be reviewed by the oncologist to determine their eligibility for this study. 6. patients must have an estimated life expectancy of at least 10 years. 7. patients must have an eastern cooperative oncology group (ecog) performance status of 0 - 2. 8. patients must have no contraindications to high dose pelvic irradiation. 9. patients must not have received prior radiation therapy to the pelvis. 10. patients must have no history of inflammatory bowel disease. 11. patients must not have received prior hormonal therapy or chemotherapy. 12. patients must not have any hormonal therapy planned as part of the therapeutic intervention. 13. patients must have no contraindication to mri scanning. 14. patients should not have an artificial hip 15. patients should not have a body mass index (bmi) of \> 32. note: bmi = weight in kg ÷ (height in metres)2 exclusion criteria: 1. subjects that do not meet inclusion criteria.

Keywords: prostate cancer imrt radiation
metformin in non-alcoholic fatty liver disease

Conditions: Fatty Liver

Summary: the study evaluates the use of the antidiabetic medicine metformin in nonalcoholic fatty liver disease.

nonalcoholic fatty liver disease (nafld) is a prevalent disorder associated with insulin resistance. metformin is a drug that has been used for several decades in the treatment of diabetes mellitus. metformin is known to improve insulin sensitivity. some authors have reported beneficial effects of metformin in nafld, others have not been able to reproduce these findings. only a few randomized controlled studies have been published so far, and there is still need for controlled trials with sufficient power to assess the efficacy of metformin in this condition. the aim of this study is to see whether treatment with metformin for 26 weeks results in reduction of liver steatosis (primary endpoint) and reduction in grade of inflammation in those with non-alcoholic steatohepatitis (nash) (secondary endpoint).

Eligibility criteria:
inclusion criteria: * histologically proven nafld less than 18 months prior to inclusion. for those with pure steatosis, alat or aspartate aminotransferase (asat) must be elevated above the upper limits of normal, and impaired glucose tolerance or diabetes mellitus type 2 must be present. * body weight within +/- 5 kg compared with the weight at the time of biopsy. exclusion criteria: * treatment for more than 1 week with metformin or glitazones the last 6 months before inclusion. * treatment with insulin. * hypersensitivity to metformin. * treatment with cimetidine. * heart failure requiring pharmacological treatment. * coronary heart disease (new york heart association \[nyha\] class 3 or 4). * chronic obstructive lung disease (moderate or severe). * breast-feeding or pregnant. * metabolic acidosis. * renal failure (male \[♂\]: creatinine \> 135 micromol/l, female \[♀\] \> 110 micromol/l). * average alcohol consumption \> 24 g/day the last year. * serum alat or serum asat \> 5 x upper limit of normal (uln) at screening. * cirrhosis. * platelets \< 100 000. * haemochromatosis. * alfa-1-antitrypsin-deficiency. * wilson's disease. * thyroid dysfunction (0.2 mu/l \< thyroid stimulating hormone \[tsh\] \< 5.0 mu/l). * chronic infection with hepatitis b or c virus or hiv. * autoimmune hepatitis (antinuclear antibodies \[ana\] \> 1/256 or smooth muscle antibodies \[sma\] \> 1/128). * primary biliary cirrhosis (antimitochondrial antibodies \[ama\] \> 1/64). * primary sclerosing cholangitis. * previous participation in another clinical trial the last 6 months. * legal incapability.

Keywords: hepatitis metformin non-alcoholic fatty liver (nafld) non-alcoholic steatohepatitis (nash) nonalcoholic fatty liver disease
immune checkpoint inhibitors and pre-existing autoimmune diseases

Conditions: Autoimmune Diseases; Advanced Cancer

Summary: the tolerance of immune checkpoint inhibitors is unknown in patients with pre-existing autoimmune conditions. this retrospective nation-wide study will assess their tolerance in patients with pre-existing autoimmune conditions who received immune checkpoint inhibitors for an advanced cancer in clinical practice.


Eligibility criteria:
inclusion criteria: * pre-existing autoimmune disease as diagnosed by the physician * immune checkpoint inhibitor therapy for an advanced cancer exclusion criteria: * auto-immune disease developed only after the start of the immune checkpoint inhibitor therapy * absence of follow-up
early use of opioid in radiation mucositis

Conditions: Nutrition Disorders; Quality of Life

Summary: this study is a superiority research to evaluate the safety and effectiveness of early use of oxycodone control release tablet for radiation mucositis in nasopharyngeal carcinoma patients.

the present study is a prospective, randomizing, case-controlled, multi-center clinical trial. 174 firstly diagnosed nasopharyngeal carcinoma patients who need radical radiation therapy will be randomly divided into either early intervention or common intervention group. oxycodone control release tablets will be used to control the pain caused by radiation oral mucositis when the pain level is mild or moderate, respectively. the primary outcome measurement is nutrition status. quality of life (qol), the clinical outcomes, and the adverse effects are also to be observed.

Eligibility criteria:
inclusion criteria: 1. histological confirmed nasopharyngeal carcinoma; 2. without historic chronic pain, no depend on analgesic drugs, no historic opioids intake; 3. plan to receive radical radiation therapy, newly to radiation for head and neck; 4. aged older or equal to 18 years old; 5. could understand and cooperate to accomplish pain evaluation and observation scales; 6. sufficient liver and kidney function: alanine aminotransferase (alt) or aspartate aminotransferase (ast) less than 2.5\* upper limit of normal (uln), serum creatinine less than 1.5\*uln; 7. without other serious critical organ dysfunction, such as heart or lung dysfunction; 8. performance status (ps) score less than 2; 9. voluntary to participate and sign informed consent document; 10. obey the rules of trail; could be followed-up on time. exclusion criteria: 1. excluded by inclusion criteria; 2. known or suspected allergy to nonsteroidal anti-inflammatory drug (nsaid) or opioid medicine; 3. unable to complete the follow-up; 4. severe uncontrollable infections of medical disorders; 5. major organ including heart, lung, kidney, or liver dysfunction; 6. with pathophysiological factors affecting drug absorption, distribution, metabolism or excretion.

Keywords: nasopharyngeal carcinoma pain oxycodone opioids radiation mucositis
cathodal tdcs in chronic migraine: neurophysiological study and pilot therapeutic trial

Conditions: Chronic Migraine

Summary: cathodal tdcs decreases the excitability of the cerebral cortex and its daily application during intercritical phase, may have a therapeutic effect in chronic migraine.

during the interictal phase, the cerebral cortex is characterised by a hyperresponsiveness to repeated sensory stimuli, manifested by a lack of habituation or adaptation of cortical responses. lack of habituation has been shown in the visual cortex in studies of visual evoked potentials (vep) during the interictal period and it is possibly explained by a reduction in the cortical pre-activation level due to thalamo-cortical dysrhythmia. just before and during the migraine attack, cortical reactivity changes drastically: habituation is restored and the amplitude increases. in chronic migraine (headache occurring on 15 or more days per month for more than 3 months with features of migraine headache on at least 8 days per month), veps habituate normally like those recorded during attacks of episodic migraine, but have in addition an increased amplitude in the 1st block of responses. chronic migraine was therefore compared to a "never ending migraine attack" accompanied by cortical hypersensitivity. in this study the investigators aim to demonstrate that cathodal tdcs over the visual cortex with simultaneous anodal tdcs over the left dorsolateral prefrontal cortex is able: 1) to reduce cortical hypersensitivity and habituation as assessed by veps and contact heat evoked nociceptive potentials (cheps), as well as to decrease pain perception assessed by quantitative sensory testing (qst) and the nociceptive blink reflex (nbr); 2) to decrease headache and migraine frequency.

Eligibility criteria:
inclusion criteria: * diagnosis of chronic migraine (ichd iii beta 1.3) with or without medication overuse exclusion criteria: * others diseases or contraindications to tdcs (epilepsy, pacemaker, metal prosthetics)